Меню
Идёт набор NCT05731830

Takotsubo Syndrome and Air Pollution

Наблюдательное Takotsubo Syndrome

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: Data extraction, Clinical follow-up.
Кому может быть актуально
Состояния в реестре: Takotsubo Syndrome. Базовые параметры: от 18 лет · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
Италия
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Официальное название

Takotsubo Syndrome and Air Pollution: the "Tako-Air" Study

Обзор

Takotsubo syndrome (TTS) is an acute and reversible form of myocardial injury characterized by typical regional wall motion abnormalities in the absence of culprit epicardial coronary artery disease frequently precipitated by significant emotional stress or serious physical illness. The clinical presentation is usually similar to acute myocardial infarction (MI), with chest pain and/or dyspnea, ST-segment elevation or depression and/or T-wave inversion on the resting electrocardiogram (ECG) and elevation of serum cardiac troponin. Although previously considered a benign disease, it is now clear that TTS is associated with severe acute complications during the acute phase including hemodynamic and electrical instability and up to 5% of in-hospital mortality. The pathogenetic mechanisms of air pollution are likely to predispose to the occurrence as well as to mediate a worse clinical presentation and outcome of TTS, proving air pollution as a TTS risk factor.

Подробное описание

Background

Takotsubo syndrome (TTS) is an acute and reversible form of myocardial injury characterized by typical regional wall motion abnormalities in the absence of culprit epicardial coronary artery disease frequently precipitated by significant emotional stress or serious physical illness. The clinical presentation is usually similar to acute myocardial infarction (MI), with chest pain and/or dyspnea, ST-segment elevation or depression and/or T-wave inversion on the resting electrocardiogram (ECG) and elevation of serum cardiac troponin. Although previously considered a benign disease, it is now clear that TTS is associated with severe acute complications during the acute phase including hemodynamic and electrical instability and up to 5% of in-hospital mortality.

Notably, despite substantial research, the risk factors and pathophysiological mechanisms of TTS are not completely understood, with several hypotheses proposed but none offering a comprehensive explanation. Catecholamine-induced myocardial injury is likely to play a central role, as an emotionally or physically triggering event precipitating the syndrome can be identified in most cases and TTS has been associated with conditions of catecholamine excess (e.g.: pheochromocytoma, central nervous system disorders) and activated specific cerebral regions. Similarly, a markedly reduced parasympathetic activity has been reported during the acute phase of TTS. Moreover, recent studies reported abnormalities in both the functional structure and activity in the areas of the brain related to both emotions and the sympathetic nervous system including the basal ganglia, the hippocampus, the amygdala, and the insula, supporting the role of limbic system dysfunction as a potential mechanism in patients with TTS. Furthermore, it has been proposed that the impaired cardiac function could be the result of an acute coronary microvascular dysfunction with impaired microvascular perfusion leading to a demand-supply mismatch and an ischemic stunning. Therefore, the risk factors for endothelial dysfunction would predispose to the occurrence of TTS.

Air pollution is a complex mixture of unwanted particulate and gaseous material released into the environment by human activities and the world's fourth leading cause of disease and death. Of interest, accumulating evidence supports a consistent relationship between increased exposure to air pollution and CV diseases such as MI and heart failure. Urban ambient air pollution, in particular combustion-derived PM, has received the greatest scientific attention due to the high density of urban populations and increasing levels of traffic-derived emissions and urbanization of societies worldwide. PM includes both organic and inorganic particles (e.g.: dust, pollen, soot, smoke, liquid droplets) and is categorized according to the aerodynamic diameter into coarse particles (2.5-10 μm in diameter; PM10), fine particles (\<2.5 μm in diameter; PM2.5), and ultrafine particles (\<0.1 μm in diameter; PM0.1). The smallest particles, such as PM2.5 and PM0.1, may contribute disproportionately to the CV toxic effects due to their large reactive surface area and their ability to penetrate deeply into the alveoli and potentially directly into the bloodstream, causing damage and dysfunction of various tissues and cells far from the lung. Gaseous pollutants, in particular nitric dioxide (NO2), ozone (O3), carbon monoxide (CO) and sulphur dioxide (SO2), have been linked to increased morbidity and mortality from CV diseases, likely in an additive manner to PM2.5, but data are still scarce and frequently inconsistent. Mechanistically, the pathogenetic mechanism of air pollution toxicity on the CV system includes oxidative stress, systemic and vascular inflammation, endothelial dysfunction, autonomic and neuroendocrine disruption, metabolic alterations, transcriptional and epigenetic reprogramming. Furthermore, the acute responses to short-term (hours) air pollution exposure include sympathoadrenal activation, release of circulating inflammatory biomarkers, alterations of endothelial function, and acute vascular modifications, such as arterial vasoconstriction and impaired vascular reactivity. The acute effects of air pollution are even more significant in the context of chronic long-term (years) exposure. Indeed, chronic air pollution exposure, by promoting the development of a vulnerable systemic state, can exponentially increase the risk of acute CV events that are likely to be precipitated by acute variations in air pollution exposure. Notably, the investigators recently demonstrated that the exposure to higher concentrations of air pollutants (especially PM2.5) is associated with the presence of vulnerable plaque features and with plaque rupture as a mechanism of coronary instability assessed by optical coherence tomography (OCT) and, moreover, with an enhanced systemic and plaque inflammatory activation. In addition, the investigators also demonstrated that a higher exposure to PM2.5 and PM10 in patients with myocardial ischemia and non-obstructive coronary artery disease is associated with coronary vasomotor abnormalities, and PM2.5 is an independent risk factor for the occurrence of epicardial spasm and MINOCA as clinical presentation.

Of interest, even though the pathogenetic mechanism of air pollution are likely to predispose to the occurrence as well as to mediate a worse clinical presentation and outcome of TTS, the relationship between air pollution and the risk of TTS as well as its clinical course has never been assessed. Furthermore, given the poor understanding of the underlying pathophysiology, there is a lack of evidence-based prevention strategies as well as interventions to reduce the incidence as well as the acute complications of TTS.

Upon this background, the investigators hypothesized that:

1. the exposure to higher levels of air pollutants in the days (short-term exposure) or years (long-term exposure) before the TTS onset could be considered as a risk factor for the occurrence of TTS; 2. the exposure to higher levels of air pollutants in the days (short-term exposure) or years (long-term exposure) before the TTS onset could be associated with a worse clinical course in terms of in-hospital complications and mortality; 3. the exposure to higher levels of air pollutants in the days (short-term exposure) or years (long-term exposure) before the TTS onset could be associated with a worse prognosis at follow-up in terms of major adverse cardiovascular events (MACE) and/or TTS recurrence.

In this context, as largely reported throughout the last ten years, time-stratified case-crossover studies represent the best model strategy. In fact, in this study design, instead of comparing exposure between people experiencing a TTS (case) and people who did not (control), pollutant concentrations before TTS diagnosis (case period) were compared with other randomly selected periods, when the subject has not experienced TTS yet (control periods). As such, each patient represents its own control. Hence, time-independent confounders, such as age, comorbidities, and smoking status are controlled by the case-crossover study design, whilst variables that change between case and control time periods are possible confounders (e.g., weather, temperature …). Stratifying by year and month is adequate for most studies and can be done as well by day of the week and temperature.

Primary objective

The primary objective of the study is to assess the relationship between either short-term or long-term exposure to increased levels of air pollutants (PM10, PM2.5, O3, NO2, benzene \[C6H6\], SO2 e CO) and onset of TTS.

Secondary objectives

* To assess the relationship between either short-term or long-term exposure to increased levels of air pollutants (PM10, PM2.5, O3, NO2, benzene \[C6H6\], SO2 e CO) and a higher rate of in-hospital complications in patients with TTS. * To assess the relationship between either a short-term or long-term exposure to increased levels of air pollutants (PM10, PM2.5, O3, NO2, C6H6, SO2 e CO) and a worse clinical outcome at follow-up in patients with TTS.

Study design

Ambispective observational case-crossover pilot study.

Study duration

The study will last 48 months from the approval of the present protocol by the local ethics committee. Enrolment will last 18 months, which will serve also to retrieve the retrospective data from the internal archives. The follow-up period will last 24 months and 6 will be dedicated to the data analysis and interpretation and drafting of scientific reports.

Air pollution data collection

The exposure of patients to air pollution compounds in the two years prior to the occurrence of TTS will be analysed. The investigators will assess: PM10, PM2.5, O3, NO2, C6H6, SO2 e CO. Residential addresses will be obtained from medical records. Annual average 24-h of pollutants levels will be measured matching each individual's home address, obtained through hospital file archive, and the "ArpaLazio" website (http://www.arpalazio.net/main/aria/sci/basedati/chimici/chimici.php). This website provides the concentration values of the following pollutants monitored by the regional automatic network since 1999 and are available for download, expressed as a concentration in micrograms per cubic meter (µg/m3): NO, NO2, NOx, PM10, PM2.5, O3, CO, C6H6, SO2. Hourly data are available for all gaseous pollutants, while the levels of PM10 and PM2.5 are expressed on a daily basis. In addition to the elementary data, the following standard calculations are available: daily averages, typical day, monthly averages and annual averages. The control units are localizable by latitude and longitude coordinates (Sampling Point of Latitude and Longitude) expressed in decimal degrees (DD) and approximated up to the 15th decimal digit, as well as uniquely identifiable by an alphanumeric code (Station Location ID). Data will be obtained from the air quality monitor closest to each participant's residence that was active for the entire year, and short-term (daily and weekly) and long-term (annual) air pollution exposure will be quantified as daily, weekly, and annual average 24-h pollutants level of measurements before TTS. In particular, daily exposure will be assessed as the average 24-h exposure to pollutants the day of TTS onset (0-day lag time between exposure and TTS), the day before (1-day lag time between exposure and TTS), 2 days before (2-day lag time between exposure and TTS), 3 days before (3-day lag time between exposure and TTS), 4 days before (4-day lag time between exposure and TTS), 5 days before (5-day lag time between exposure and TTS), 6 days before (6-day lag time between exposure and TTS) and 7 days before (7-day lag time between exposure and TTS). Similarly, weekly exposure will be assessed as the average 24-h exposure to pollutants the week of TTS onset (0-week lag time between exposure and TTS), the two week before (1-week lag time between exposure and TTS), the three weeks before (2-week lag time between exposure and TTS), and the four week before (3-week lag time between exposure and TTS). Finally, long-term exposure will be assessed as the annual average 24-h pollutants level of measurements of 2 years before TTS. Of note, this methodology to assess air pollution has been extensively validated and used in previous studies. Only patients with 2 years or more of available data on air pollution exposure prior to TTS will be included.

Sample size calculation

To the best of our knowledge, there is no previous literature focusing on air pollutants effects in Takotsubo syndrome (TTS), hence this reflects as a pilot study. As such, no formal sample size calculation is needed. Common rules of thumb for pilot studies by Browne (1995) refer to 30 subjects as a minimum sample size. Based on data retrievable from the archives since 2016 and on an estimated 30 subje

Вмешательства

  • Другое Data extraction
    The exposure of patients to air pollution compounds in the two years prior to the occurrence of TTS will be analysed. We will investigate: PM10, PM2.5, O3, NO2, C6H6, SO2 e CO. Residential addresses will be obtained from medical records. Annual average 24-h of pollutants levels will be measured matching each individual's home address, and the "ArpaLazio" website (http://www.arpalazio.net/main/aria/sci/basedati/chimici/chimici.php), which provides the concentration of NO, NO2, NOx, PM10, PM2.5, O
  • Другое Clinical follow-up
    All patients will undergo a clinical follow-up by telephonic interview and/or clinical visit at 6, 12, 24, 36, 48 and 60 months from hospital discharge, during which the incidence of MACE, defined as the composite of all-cause mortality, non-fatal MI, transient ischemic attack (TIA)/stroke, and hospitalization for heart failure, and the recurrence of TTA in the past months will be investigated and collected.

Первичные конечные точки

  • Association between levels of PM10 air pollutant and TTS [Срок оценки: Up to 30 days]
  • Association between levels of PM2.5 air pollutant and TTS [Срок оценки: Up to 30 days]
  • Association between levels of O3 air pollutant and TTS [Срок оценки: Up to 30 days]
  • Association between levels of NO2 air pollutant and TTS [Срок оценки: Up to 30 days]
  • Association between levels of benzene [C6H6] air pollutant and TTS [Срок оценки: Up to 30 days]
  • Association between levels of SO2 air pollutant and TTS [Срок оценки: Up to 30 days]
  • Association between levels of CO air pollutant and TTS [Срок оценки: Up to 30 days]
Вторичные конечные точки (12)
  • Association between levels of PM10 air pollutant and in-hospital complications [Срок оценки: Up to 30 days]
  • Association between levels of PM2.5 air pollutant and in-hospital complications [Срок оценки: Up to 30 days]
  • Association between levels of O3 air pollutant and in-hospital complications [Срок оценки: Up to 30 days]
  • Association between levels of NO2 air pollutant and in-hospital complications [Срок оценки: Up to 30 days]
  • Association between levels of benzene [C6H6] air pollutant and in-hospital complications [Срок оценки: Up to 30 days]
  • Association between levels of SO2 air pollutant and in-hospital complications [Срок оценки: Up to 30 days]
  • Association between levels of CO air pollutant and in-hospital complications [Срок оценки: Up to 30 days]
  • Association between levels of PM10 air pollutant and MACE at follow-up [Срок оценки: Up to 5 years]
  • Association between levels of PM2.5 air pollutant and MACE at follow-up [Срок оценки: Up to 5 years]
  • Association between levels of O3 air pollutant and MACE at follow-up [Срок оценки: Up to 5 years]
  • Association between levels of NO2 air pollutant and MACE at follow-up [Срок оценки: Up to 5 years]
  • Association between levels of benzene [C6H6] air pollutant and MACE at follow-up [Срок оценки: Up to 5 years]

Критерии участия

Критерии включения

  • Age ≥18 years.
  • Diagnosis of TTS.
  • Available data for short-term and/or long-term exposure to air pollutants (see below).
  • Written informed consent to participate.

Критерии исключения

  • Age <18 years.
  • Not available data for short-term and/or long-term exposure to air pollutants.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Модель наблюдения
Случай-кроссовер

Центры проведения

Италия · 1 центр
  • Fondazione Policlinico Universitario A. Gemelli IRCCS — Rome

Публикации

  • Ghadri JR, Wittstein IS, Prasad A, Sharkey S, Dote K, Akashi YJ, Cammann VL, Crea F, Galiuto L, Desmet W, Yoshida T, Manfredini R, Eitel I, Kosuge M, Nef HM, Deshmukh A, Lerman A, Bossone E, Citro R, Ueyama T, Corrado D, Kurisu S, Ruschitzka F, Winchester D, Lyon AR, Omerovic E, Bax JJ, Meimoun P, Tarantini G, Rihal C, Y-Hassan S, Migliore F, Horowitz JD, Shimokawa H, Luscher TF, Templin C. Intern PMID 29850871
  • Lyon AR, Citro R, Schneider B, Morel O, Ghadri JR, Templin C, Omerovic E. Pathophysiology of Takotsubo Syndrome: JACC State-of-the-Art Review. J Am Coll Cardiol. 2021 Feb 23;77(7):902-921. doi: 10.1016/j.jacc.2020.10.060. PMID 33602474
  • Santoro F, Nunez Gil IJ, Stiermaier T, El-Battrawy I, Guerra F, Novo G, Guastafierro F, Tarantino N, Novo S, Mariano E, Romeo F, Romeo F, Capucci A, Bahlmann E, Zingaro M, Cannone M, Caldarola P, Marchetti MF, Montisci R, Meloni L, Thiele H, Di Biase M, Almendro-Delia M, Sionis A, Akin I, Eitel I, Brunetti ND. Assessment of the German and Italian Stress Cardiomyopathy Score for Risk Stratification PMID 31389988
  • Gili S, Cammann VL, Schlossbauer SA, Kato K, D'Ascenzo F, Di Vece D, Jurisic S, Micek J, Obeid S, Bacchi B, Szawan KA, Famos F, Sarcon A, Levinson R, Ding KJ, Seifert B, Lenoir O, Bossone E, Citro R, Franke J, Napp LC, Jaguszewski M, Noutsias M, Munzel T, Knorr M, Heiner S, Katus HA, Burgdorf C, Schunkert H, Thiele H, Bauersachs J, Tschope C, Pieske BM, Rajan L, Michels G, Pfister R, Cuneo A, Jaco PMID 31098611
  • Lyon AR, Bossone E, Schneider B, Sechtem U, Citro R, Underwood SR, Sheppard MN, Figtree GA, Parodi G, Akashi YJ, Ruschitzka F, Filippatos G, Mebazaa A, Omerovic E. Current state of knowledge on Takotsubo syndrome: a Position Statement from the Taskforce on Takotsubo Syndrome of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2016 Jan;18(1):8-27. doi: 10.1002/ PMID 26548803
  • Ortak J, Khattab K, Barantke M, Wiegand UK, Bansch D, Ince H, Nienaber CA, Bonnemeier H. Evolution of cardiac autonomic nervous activity indices in patients presenting with transient left ventricular apical ballooning. Pacing Clin Electrophysiol. 2009 Mar;32 Suppl 1:S21-5. doi: 10.1111/j.1540-8159.2008.02221.x. PMID 19250097
  • Suzuki H, Matsumoto Y, Kaneta T, Sugimura K, Takahashi J, Fukumoto Y, Takahashi S, Shimokawa H. Evidence for brain activation in patients with takotsubo cardiomyopathy. Circ J. 2014;78(1):256-8. doi: 10.1253/circj.cj-13-1276. Epub 2013 Nov 28. PMID 24284957
  • Hiestand T, Hanggi J, Klein C, Topka MS, Jaguszewski M, Ghadri JR, Luscher TF, Jancke L, Templin C. Takotsubo Syndrome Associated With Structural Brain Alterations of the Limbic System. J Am Coll Cardiol. 2018 Feb 20;71(7):809-811. doi: 10.1016/j.jacc.2017.12.022. No abstract available. PMID 29447745

Идентификаторы

NCT: NCT05731830 · 5290

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗